Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-144

Typical Stormer, playing the man not the ball. I think Nina is great for what it's worth. And I also think that the board were abit blindsided by these results as they are so perplexed/intrigued by the placebo patients receiving a reduction in albuminuria. The talk of legacy impact seems to be something nobody thought about (maybe the 6 week washout should have been longer? Maybe the legacy impact is a huge positive and shows the real effectiveness of DMX 200) only more data analysis will give the answers, we need to see detailed analysis of the cohort that received dmx200 first Vs the cohort that received placebo first. It might highlight something epic similar to the data analysis from phase 2a which showed up diabetics as being good responders. So I personally still believe in the compound, in the team and where Dimerix are going, it's just a bump in the road and means we have to wait a little longer